Hong Kong-based biotech company Insilico Medicine has announced the launch of COVIDomic, a research support platform tailored to the Covid-19 pandemic.
COVIDomic enables scientists to use integrated anonymised patient data with a variety of existing data sets, before applying bioinformatics and artificial intelligence (AI). The platform is intended to help stratify Covid-19 patients more effectively, as well as understanding the disease trajectory and identifying relevant disease pathways and targets.
Insilico Medicine founder and CEO Alex Zhavoronkov said: “COVIDomic is an open access tool to stratify risk and severity from multimodal data sets, including multi-omics data. Insilico Medicine's AI-driven generative biology approach is a unique offering in the marketplace. We are part of many Covid-19 consortiums and collaborations but COVIDomic is a system that will help scientists and researchers alike to predict the severity of the disease.”